Početna stranicaAMPH • NASDAQ
add
Amphastar Pharmaceuticals Inc
Preth. zaklj. cijena
36,36 $
Dnevni raspon
35,85 $ - 37,46 $
Godišnji raspon
34,73 $ - 56,88 $
Tržišna kapitalizacija
1,80 mlr. USD
Prosječna količina
594,37 tis.
P/E omjer
12,42
Prinos dividende
-
Glavno tržište vrijednosnica
NASDAQ
Vijesti s tržišta
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
| (USD) | ruj 2024.info | Godišnja promjena |
|---|---|---|
Prihod | 191,21 mil. | 5,90 % |
Operativni troškovi | 44,89 mil. | 25,66 % |
Neto dohodak | 40,43 mil. | −17,86 % |
Neto profitabilnost | 21,14 | −22,45 % |
Zarada po dionici | 0,96 | −16,52 % |
EBITDA | 70,45 mil. | −17,41 % |
Efektivna porezna stopa | 15,21 % | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
| (USD) | ruj 2024.info | Godišnja promjena |
|---|---|---|
Gotovinska i kratkoročna ulaganja | 250,49 mil. | −16,47 % |
Ukupna imovina | 1,55 mlr. | 0,04 % |
Ukupne obveze | 817,50 mil. | −13,90 % |
Ukupni kapital | 727,68 mil. | — |
Dionice u optjecaju | 48,08 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | 2,42 | — |
Povrat imovine | 9,39 % | — |
Povrat kapitala | 10,60 % | — |
Tok novca
Neto promjena novca
| (USD) | ruj 2024.info | Godišnja promjena |
|---|---|---|
Neto dohodak | 40,43 mil. | −17,86 % |
Gotovina od poslovanja | 59,96 mil. | −6,80 % |
Gotovina iz ulaganja | −34,59 mil. | −11,02 % |
Gotovina iz financiranja | −22,82 mil. | −126,34 % |
Neto promjena novca | 2,50 mil. | −97,91 % |
Slobodan tok novca | 25,06 mil. | −49,93 % |
Više
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic. In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally.
In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case.
In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn. Wikipedia
Osnovano
1996
Web-lokacija
Zaposlenici
1.761
